Clinical trial

Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study

NCT06805812

StatusRECRUITING

Study typeOBSERVATIONAL

Start date2023-05-01

PhaseN/A

Study timeline

Study start (actual)2023-05-01Date precision: day

Registry last updated2025-02-03

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Breast Adenocarcinomaunresolved

Breast Cancer Stage IVunresolved

Breast Cancer, Metastaticunresolved

Breast Carcinomaunresolved

Breast Diseasesunresolved

Breast Neoplasmsunresolved

Breast Neoplasms, Maleunresolved

Breast Cancerunresolved

Breast Cancer With Metastatic Bone Diseaseunresolved

Breast Cancersunresolved

Breast Neoplasmunresolved

Breast Tumorsunresolved

HR+ HER2- Men, Pre/Postmenopausal Advanced Breast Cancerunresolved

HR+ Advanced or Metastatic Breast Cancerunresolved

HR+/HER2- Breast Cancerunresolved

HRpos Breast Neoplasmsunresolved

HR-positive, HER2-negative Advanced Breast Cancerunresolved

HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancerunresolved

HR-positive Breast Cancerunresolved

Hormone Receptor-Positive Breast Cancerunresolved

Hormone Receptor Positive Breast Adenocarcinomaunresolved

Hormone Receptor Positive Breast Carcinomaunresolved

Hormone Receptor Positive Breast Neoplasmsunresolved

Hormone Receptor Positive HER-2 Negative Breast Cancerunresolved

Hormone Receptor Positive Malignant Neoplasm of Breastunresolved

Hormone Receptor Positive Metastatic Breast Cancerunresolved

Hormone Receptor Positive, HER2 Negative Breast Cancerunresolved

Hormone Receptor Negative Breast Cancerunresolved

Hormone Receptor Positive, HER2-negative, Advanced Breast Cancerunresolved

Hormone Receptor Positive Breast Cancerunresolved

Hormone Receptor Positive (ER+/PR+, and Her2-) Metastatic Breast Cancerunresolved

Hormone Receptor Positive, HER2-negative Neoplasmsunresolved

Hormone Receptor Positive, HER2-low Neoplasmsunresolved

Hormone Receptor Positive (HR+), HER2-negative Breast Cancerunresolved

Hormone Receptor (HR)-Positive Breast Cancerunresolved

Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancerunresolved

Palbociclibunresolved

Ribociclibunresolved

Abemaciclibunresolved

CDK4/6 Inhibitorunresolved

CDK4/6 Inhibitorsunresolved

Interventions

PalbociclibDRUG · verified · RxNorm: palbociclib

RibociclibDRUG · verified · RxNorm: ribociclib

AbemaciclibDRUG · verified · RxNorm: abemaciclib

Sponsors & collaborators

Fondazione IRCCS Istituto Nazionale dei Tumori, Milanolead sponsor

European Institute of Oncology, Italycollaborator

Humanitas Research Hospital IRCCS, Rozzano-Milancollaborator

Azienda Socio Sanitaria Territoriale degli Spedali Civili di Bresciacollaborator

OSPEDALE ASST CREMONAcollaborator

IOV Oncologico Veneto Padovacollaborator

ASST Fatebenefratelli Saccocollaborator

IRCCS Fondazione Salvatore Maugeri, Pavia, Italycollaborator

IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori Meldolacollaborator

Azienda Ospedaliero-Universitaria di Modenacollaborator

Azienda Ospedaliero Universitaria Maggiore della Caritacollaborator

A.O.U. Federico II, Napolicollaborator

San Raffaele University Hospital, Italycollaborator

Centro di Riferimento Oncologico - Avianocollaborator

Azienda Socio-Sanitaria Territoriale Larianacollaborator

Azienda ULSS 3 Serenissima, Ospedale di Miranocollaborator

Azienda Ospedaliero Universitaria Policlinico Umberto I, Romacollaborator

Fondazione IRCCS Policlinico San Matteo di Paviacollaborator

IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italycollaborator

Fondazione Policlinico Universitario Agostino Gemelli IRCCScollaborator

Azienda Ospedaliero-Universitaria Careggicollaborator

Humanitas, Istituto Clinico Catanesecollaborator

Istituto Nazionale Tumori IRCCS - Fondazione G. Pascalecollaborator

Fondazione Policlinico Universitario Campus Bio-Medicocollaborator

Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinicocollaborator

Mapped research locations

MilanItaly4 RomaItaly3 NaplesItaly2 PaviaItaly2 GenovaItaly1 PadovaItaly1 FlorenceItaly1 BresciaItaly1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06805812 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.